WST forecasts $8.85-$9.05 adjusted EPS for 2026 after Q2 revenue hit $872 million, exceeding expectations.
West Pharmaceutical Services updated its 2026 guidance, projecting 10%-11% organic revenue growth and adjusted earnings per share of $8.85-$9.05. The company reported Q2 2026 revenue of $872 million, surpassing internal forecasts and driving the upward revision.
The revised outlook follows a stronger-than-expected second quarter, with revenue growth accelerating from prior periods. Analysts had anticipated modest gains, but the $872 million print reflected robust demand across key segments. Management attributed the performance to operational execution and market expansion.
Shares showed limited immediate reaction during after-hours trading, as investors digested the updated targets. The company also announced a leadership transition, though details on timing or successors were not disclosed.